Why Is Scribe Therapeutics (SCTX) Stock Down -7.00% Today?

Key Takeaways

• SCTX fell 7.00% to $15.80 in Friday morning trading, down $1.19 from Thursday's $16.99 close.
• The primary catalyst is the third-quarter 2026 report: collaboration revenue of $1.64 million badly missed the roughly $3.72 million consensus and dropped 91.9% from a year earlier.
• Partially offsetting the miss, GAAP loss of $0.68 per share beat expectations by about $0.20, and cash of $174.2 million is expected to fund operations into the first half of 2029.
• Secondary drivers: no new STX-1150 Phase 1 data until the first half of 2027, plus a softer biotech tape, with the sector benchmark down about 1.6%.
• News Significance Score: 26/100 — moderate, largely financial earnings news paired with a decline close to the stock's ordinary daily swing.
• Traders are watching the STX-1150 single-ascending-dose readout in the first half of 2027, collaboration revenue trends with Sanofi and Eli Lilly, and management's investor meetings in London from Nov. 15–20.
• Get more detail on Price Targets, Earnings, and Forecast pages for a fuller view of the setup.
• Explore Trending AI Robots to see which automated strategies are working in the current market.

Opening Summary

Scribe Therapeutics Inc. (SCTX) is a clinical-stage biotechnology company based in Alameda, California, that engineers in vivo CRISPR-based genetic medicines for cardiometabolic disease. Its lead asset, STX-1150, is an epigenetic silencing therapy targeting PCSK9 to lower LDL cholesterol, with earlier programs aimed at Lp(a) and triglycerides. The stock is trading at $15.80, down 7.00% from the prior close of $16.99, and sits near session lows after opening at $16.23. The decline is a delayed reaction to the company's third-quarter results, published after Thursday's closing bell, which showed a steep shortfall in collaboration revenue despite a narrower-than-expected per-share loss.

Q3 Revenue Miss Drives the Post-Earnings Slide

The dominant factor is the quarterly report. Collaboration revenue came in at $1.636 million versus a consensus near $3.72 million and $20.1 million in the year-earlier quarter, a 91.9% decline. For the first nine months of 2026, revenue totaled $5.79 million against $42.1 million a year earlier.

Management attributed the drop to lower revenue recognized under the Eli Lilly collaboration, as reimbursable research activity slowed. That matters because the company's top line is almost entirely milestone- and reimbursement-based, so timing shifts in partner programs can swing reported revenue by tens of millions of dollars from one quarter to the next. Investors also noted a sequential widening of the net loss to $9.86 million, or $0.68 per share, from $6.5 million in the second quarter, alongside a rise in general and administrative expense to $4.24 million.

What Softened the Blow — and Why It Wasn't Enough

The quarter was not a clean negative. The $0.68 per-share loss beat the roughly $0.88 consensus, research and development spending fell to $8.26 million from $14.4 million a year earlier, and cash, equivalents and marketable securities stood at $174.2 million following roughly $140 million of net IPO proceeds. Scribe reiterated that this balance funds operations into the first half of 2029, removing near-term dilution pressure.

The offsetting positives were mostly backward-looking, however. The third quarter brought no new clinical data on STX-1150, which is enrolling patients in a first-in-human Phase 1 trial, and the company continues to guide initial safety, tolerability and LDL-C-lowering data to the first half of 2027. With the next major value inflection roughly six months or more away, there is little fresh pipeline news to absorb a revenue miss.

Market Context and Trading Activity

The move is largely company-specific rather than sector-driven, though the backdrop did not help. The iShares Biotechnology ETF (XBI) was down about 1.6% and the iShares Nasdaq Biotechnology ETF (IBB) roughly 1%, while the broad market slipped only modestly. Scribe's 7% decline is therefore several times the sector's drop, pointing to the earnings release as the decisive variable.

Trading volume in the first half hour was light relative to the roughly 370,000 shares the stock has averaged daily over the past month, suggesting orderly selling rather than a capitulation flush. Technically, the shares remain well below their 50-day moving average near $21.40 and far below the $39.60 post-IPO high set in August, keeping the intermediate trend negative. Short interest of about 1.67 million shares, equal to roughly a quarter of the small public float, remains a source of two-way volatility.

News Significance Score

The score runs from 0, meaning no meaningful news and a normal move for the stock, to 100, meaning transformative news and an extreme, rare price move.

This event scores 26 out of 100. The verified news is moderate: a sizable revenue miss and a swing to a larger net loss, offset by a per-share beat and a long cash runway, with no clinical or regulatory development attached. The price response was equally unremarkable by this stock's standards. The 7.00% decline was only about 1.25 times the typical absolute daily move of roughly 5.6% over the past 60 sessions, and 19 of those sessions produced swings of 7% or more. Moderate news combined with an ordinary-sized move for a volatile micro-cap produces a low score.

What Comes Next for SCTX

The pivotal item is the STX-1150 Phase 1 single-ascending-dose data expected in the first half of 2027, which will be the first human test of the ELXR epigenetic silencing platform. Before then, investors will parse collaboration revenue trends for signs that Lilly and Sanofi activity is reaccelerating, and watch for updates on STX-1200 and STX-1400, both targeted for clinical entry as early as 2027 with support from non-dilutive CIRM grants. Management's one-on-one meetings during London Life Sciences Week, Nov. 15–20, could generate incremental commentary.

Risks cut both ways: sell-side coverage remains uniformly bullish with an average 12-month target of $57 across four analysts, last updated in early September and untested by this quarter's revenue line. A prolonged slide in partner-funded revenue, further losses, or any safety signal in the Phase 1 trial would challenge that stance, while continued cash discipline limits financing risk through 2028.

Trending AI Robots

Tickeron's Trending AI Robots page curates the automated trading strategies performing best under current market conditions. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers are surfaced in this section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the lineup rotates as market conditions shift. Reviewing the trending list is a practical way to see which approaches are working right now — explore the page to find a bot that matches your own trading style.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume